Semantic Scholar uses AI to extract papers important to this topic.
Treatment of genotype 1 hepatitis C virus (HCV) infection with combination directly acting antivirals (DAA) for 8-24… Expand BACKGROUND
Direct-acting antiviral drugs have a high cure rate and favourable tolerability for patients with hepatitis C virus… Expand BACKGROUND
Hepatitis C virus (HCV) RNA loads serve as predictors of treatment response during interferon-based therapy. We… Expand AbstractBackground
As treatment for chronic hepatitis C (HCV) virus has evolved to all-oral, interferon-free directly acting… Expand BACKGROUND
Treatment of chronic hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) for 6 weeks achieves… Expand ABSTRACT GS-9451 is a selective hepatitis C virus (HCV) NS3 protease inhibitor in development for the treatment of genotype 1… Expand BACKGROUND
GS-9451 is a novel inhibitor of the HCV NS3/4A protease and demonstrates potent in vitro suppression of HCV genotype 1… Expand The discovery of GS-9451 is reported. Modification of the P3 cap and P2 quinoline with a series of solubilizing groups led to the… Expand ABSTRACT GS-9451, a novel hepatitis C virus (HCV) nonstructural 3/4a (NS3/4a) protease inhibitor, is highly active in patients… Expand ABSTRACT The high genetic variation of hepatitis C virus (HCV) results in rapid selection of drug resistance mutations (DRMs… Expand